Avalon GloboCare Corp. Stock

Equities

ALBT

US05344R2031

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
0.479 USD +9.11% Intraday chart for Avalon GloboCare Corp. +6.35% -0.83%
Sales 2022 1.16M Sales 2023 -7.33M Capitalization 5.31M
Net income 2022 -11M Net income 2023 -16M EV / Sales 2022 46.8 x
Net Debt 2022 2.58M Net Debt 2023 8.22M EV / Sales 2023 -1.85 x
P/E ratio 2022
-4.07 x
P/E ratio 2023
-0.3 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 38.63%
More Fundamentals * Assessed data
Dynamic Chart
Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference CI
Avalon GloboCare Corp. announced that it has received $2.70275 million in funding from Mast Hill Management, LLC CI
Avalon GloboCare Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference CI
North American Morning Briefing : Stock Futures -2- DJ
Avalon GloboCare Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Traders Await -2- DJ
North American Morning Briefing : Powell Awaited -2- DJ
Avalon GloboCare Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Avalon GloboCare Corp. announced that it has received $0.665 million in funding from Mast Hill Management, LLC, FirstFire Capital Management LLC CI
Avalon GloboCare Corp. announced that it expects to receive $0.665 million in funding from Mast Hill Management, LLC, FirstFire Capital Management LLC CI
Top Midday Gainers MT
Avalon Says Laboratory Services Launches New Tuberculosis Test; Shares Rise MT
North American Morning Briefing : Treasury Yields Keep Pushing Higher DJ
Avalon GloboCare Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
1 day+9.11%
1 week+6.35%
Current month+62.37%
1 month+65.12%
3 months+54.52%
6 months-4.24%
Current year-0.83%
More quotes
1 week
0.41
Extreme 0.4074
0.48
1 month
0.27
Extreme 0.2713
1.44
Current year
0.24
Extreme 0.24
1.44
1 year
0.24
Extreme 0.24
1.81
3 years
0.24
Extreme 0.24
11.90
5 years
0.24
Extreme 0.24
28.00
10 years
0.24
Extreme 0.24
135.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 16-09-13
Director of Finance/CFO 56 06-12-31
Sales & Marketing 46 16-10-09
Members of the board TitleAgeSince
Director/Board Member 78 18-07-30
Director/Board Member 81 17-11-06
Director/Board Member 56 18-07-04
More insiders
Date Price Change Volume
24-06-21 0.479 +9.11% 59,378
24-06-20 0.439 +4.52% 156,936
24-06-18 0.42 +0.72% 940,229
24-06-17 0.417 -7.42% 220,475
24-06-14 0.4504 -4.21% 319,913

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm EDT

More quotes
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. It is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.
More about the company